Top Markets
#1 QuantixAI QuantixAI +102.94%
#2 龙虾 (Lobster) 龙虾 (Lobster) +29.51%
#3 MetaDAO MetaDAO +29.20%
#4 Rain Rain +24.16%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +19.73%
#6 Bedrock Bedrock +19.11%
#7 Pons Pons +17.61%
#8 Prom Prom +16.34%
#9 Humanity Humanity +14.45%
#10 Ontology Gas Ontology Gas +14.45%
Coin of the day
QuantixAI QuantixAI
設定
言語
日本
通貨
USD
テーマ
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
株式のランク #2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
株価
$70.50
最終同期: 2025-11-14
時価総額
$7.33B
変化（1日）
0.00%
変化（1年）
116.32%
国
US
取引 Metsera, Inc. (MTSR)

カテゴリー

Healthcare
Metsera, Inc.（MTSR）のP/B比率
2026 時点のP/B比率 TTM: 0
Metsera, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
Metsera, Inc. の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH